Karyopharm Therapeutics Inc. (NASDAQ:KPTI) SVP Christopher Brett Primiano sold 2,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $22,000.00. Following the completion of the transaction, the senior vice president now owns 12,881 shares in the company, valued at $141,691. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Christopher Brett Primiano also recently made the following trade(s):

  • On Monday, June 26th, Christopher Brett Primiano sold 805 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.03, for a total transaction of $8,074.15.
  • On Tuesday, August 29th, Christopher Brett Primiano sold 2,195 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $21,950.00.

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) opened at 10.52 on Wednesday. The firm’s market cap is $495.89 million. Karyopharm Therapeutics Inc. has a 12-month low of $6.27 and a 12-month high of $14.63. The company has a 50 day moving average of $9.40 and a 200-day moving average of $9.83.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. During the same quarter in the prior year, the company earned ($0.84) EPS. Karyopharm Therapeutics’s quarterly revenue was down 95.0% compared to the same quarter last year. Equities research analysts forecast that Karyopharm Therapeutics Inc. will post ($2.67) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/christopher-brett-primiano-sells-2000-shares-of-karyopharm-therapeutics-inc-kpti-stock/1574956.html.

Several large investors have recently modified their holdings of KPTI. Teachers Advisors LLC boosted its stake in shares of Karyopharm Therapeutics by 15.0% in the 4th quarter. Teachers Advisors LLC now owns 41,436 shares of the company’s stock valued at $389,000 after purchasing an additional 5,419 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Karyopharm Therapeutics by 175.8% in the 1st quarter. Nationwide Fund Advisors now owns 56,527 shares of the company’s stock valued at $726,000 after purchasing an additional 36,031 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Karyopharm Therapeutics by 103.9% in the 1st quarter. Russell Investments Group Ltd. now owns 74,882 shares of the company’s stock valued at $962,000 after purchasing an additional 38,158 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Karyopharm Therapeutics by 114.6% in the 1st quarter. Wells Fargo & Company MN now owns 43,606 shares of the company’s stock valued at $560,000 after purchasing an additional 23,284 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Karyopharm Therapeutics by 61.7% in the 1st quarter. Bank of New York Mellon Corp now owns 181,602 shares of the company’s stock valued at $2,332,000 after purchasing an additional 69,315 shares in the last quarter. Institutional investors own 58.97% of the company’s stock.

A number of research analysts have recently issued reports on KPTI shares. ValuEngine downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 25th. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 24th. Robert W. Baird restated an “outperform” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Thursday, July 6th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, July 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $15.67.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.